DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 07:41:17 2024-05-31 EDT | ||
| 377.5 EUR / 378.87 EUR | +0.06% |
|
| Current month | +5.36% | ||
| 1 month | +5.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 376.9 | -0.28% |
| 24-05-30 | 378 | -0.59% |
| 24-05-29 | 380.2 | -1.26% |
| 24-05-28 | 385.1 | -0.03% |
| 24-05-27 | 385.2 | +0.34% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 07:33 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8T |
| ISIN | DE000ME7D8T4 |
| Date issued | 2024-01-23 |
| Maturity | 2024-12-20 (204 Days) |
| Parity | 1 : 1 |
| Emission price | 364.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 385.2 € |
|---|---|
| Lowest since issue | 351.3 € |
| Spread | 1.37 € |
| Spread % | 0.36% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
443
USD
Average target price
462.8
USD
Spread / Average Target
+4.46%
- Stock Market
- Certificates
- Certificat
